LIMN on Nasdaq

Liminatus Pharma, Inc.

Liminatus Pharma, Inc. is an American biological products company based in Fullerton.1 Its shares trade on Nasdaq under the symbol LIMN.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerLIMN on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersCerritos, California1
  • Incorporated inDE2
  • Business address12611 Hiddencreek Way, Unit C, Cerritos, Ca 907032
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$3.0M in 2025−11% since 2024
-$4.0M-$3.0M-$2.0M-$1.0M02024: -$3.3M-$3.3M20242025: -$3.0M-$3.0M2025−11%
Net income3-$10.2M in 2025+188% since 2024
-$15.0M-$10.0M-$5.0M02024: -$3.5M-$3.5M20242025: -$10.2M-$10.2M2025+188%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
General and administrative$3.0M$644.6K
Research and development$2.7M
Total operating expenses$3.0M$3.3M
Loss from operations-$3.0M-$3.3M
Interest expense, related parties-$215.9K-$338.9K
Interest income$76.6K$122.5K
Forgiveness of unrelated vendor payables$2.1M
Change in fair value of deferred underwriting fee - paid in common stock-$196.0K
Change in the fair value of warrant liability$54.3K$0
Loss on exchange of common stock for warrants-$1.7M
Fair value of common stock to be issued for contingent liability-$7.4M
Total other expense, net-$7.2M-$216.4K
Net loss-$10.2M-$3.5M
Weighted average shares outstanding - basic (in shares)23.8M shares17.5M shares
Weighted average shares outstanding - diluted (in shares)23.8M shares17.5M shares
Basic net loss per share (in dollars per share)-$0.43-$0.20
Diluted net loss per share (in dollars per share)-$0.43-$0.20

Compare Liminatus Pharma, Inc. with another company

Corporate structure

Liminatus Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Liminatus Pharma, Inc.

  • Samda Biolab Co., Ltd. Filed SCHEDULE 13G on Liminatus Pharma, Inc., latest Jul 22, 2026
  • Valetudo Therapeutics LLC Filed SCHEDULE 13D/A on Liminatus Pharma, Inc., latest Jul 14, 2026 (2 filings since May 7, 2025)
  • Ewon Comfortech Co., Ltd. Filed SCHEDULE 13G/A on Liminatus Pharma, Inc., latest Jul 6, 2026 (2 filings since Jun 26, 2025)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G on Liminatus Pharma, Inc., latest Feb 20, 2026
  • KH Feelux Co., Ltd Filed SCHEDULE 13G on Liminatus Pharma, Inc., latest Jun 27, 2025
  • Apple Association 1st Nongae Filed SCHEDULE 13G on Liminatus Pharma, Inc., latest Jun 26, 2025
  • Peony Association 1st Red Filed SCHEDULE 13G on Liminatus Pharma, Inc., latest Jun 26, 2025
  • Iris Acquisition Holdings LLC Filed SCHEDULE 13D on Liminatus Pharma, Inc., latest May 8, 2025
  • Liminatus Pharma, Inc. Cerritos, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Liminatus Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$12.2K3 Dec 31, 2025$9413 Dec 31, 2024+1198.7%

Properties, in its own words

On July 17, 2025, the Company entered into a sublease in Cerritos, CA for office space of approximately 1,320 sq. ft. commencing September 1, 2025 and ending June 30, 2026. The monthly rent is $2,784 per month.

We believe the property has been adequately maintained, is generally in good condition, and is suitable and adequate for our business.

Item 2 of the 10-K filed Mar 31, 2026.6

Leadership

Who has led Liminatus Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Scott Dam2025–now
  • Chief financial officerScott Dam Apr 30, 2025 to now7
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorChris Kim named Jun 18, 202616

Former names

  • Iris Parent Holding Corp.May 2, 2023 to Feb 7, 20252

Timeline

  1. Sep 29, 20268-K Listing notice or transfer; Regulation FD disclosure17
  2. Aug 18, 20268-K Listing notice or transfer; Change to shareholders' rights; Bylaws or fiscal year changed18
  3. Aug 4, 20268-K Shareholder vote19
  4. Jul 30, 20268-K Other events20
  5. Jul 24, 20268-K Listing notice or transfer; Other events21
  6. Jul 6, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares22
  7. Jun 3, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights23
  8. May 27, 20268-K Listing notice or transfer24
  9. May 20, 20268-K Entered a material agreement25
  10. Mar 4, 20268-K Bylaws or fiscal year changed26
  11. Feb 18, 20268-K Entered a material agreement; Other events27
  12. Feb 9, 20268-K Entered a material agreement; Unregistered sale of shares28

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202629

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

108 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 25 major events, 16 insider forms, 10 large holders, 1 private raises, 50 other. The latest 20:

  1. Sep 29, 20268-K EDGAR
  2. Aug 18, 20268-K EDGAR
  3. Aug 14, 202610-Q EDGAR
  4. Aug 4, 20268-K EDGAR
  5. Jul 30, 20268-K EDGAR
  6. Jul 24, 20268-K EDGAR
  7. Jul 22, 2026SCHEDULE 13G EDGAR
  8. Jul 14, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jul 14, 2026SCHEDULE 13D/A EDGAR
  10. Jul 13, 2026DEF 14A EDGAR
  11. Jul 6, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Jul 6, 20263 OWNERSHIP DOCUMENT EDGAR
  13. Jul 6, 2026SCHEDULE 13G/A EDGAR
  14. Jul 6, 20268-K EDGAR
  15. Jun 30, 2026PRE 14A EDGAR
  16. Jun 24, 2026S-1 EDGAR
  17. Jun 18, 2026D EDGAR
  18. Jun 3, 20268-K EDGAR
  19. Jun 3, 2026424B3 EDGAR
  20. May 27, 20268-K EDGAR

The 108 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 3, 2026Raised $1.9 million in a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How Liminatus Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLiminatus Pharma, Inc.1
  • CIK0001971387
  • Employer ID (EIN)93-27107486
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company6
  • Incorporated inDelaware6
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address12611 Hiddencreek Way, Unit C, Cerritos, CA 907031
  • Phone213-273-54531
  • Shares outstanding67,160,362 as of Aug 14, 20265
  • Public float$221.0M as of Jun 30, 20256
  • AuditorWithumSmith+Brown, PC, Whippany, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceMay 2, 20231
  • Filings108 in all: 8-K (23), 3 (14), CORRESP (13), UPLOAD (9), SCHEDULE 13G (6), 10-Q (5), S-4/A (5), 424B3 (4)1
    All 26 form types

    EFFECT (4), POS AM (3), S-1 (3), 4 (2), DRS (2), NT 10-Q (2), SCHEDULE 13D (2), 10-K (1), 424B4 (1), 8-K/A (1), 8-K12B (1), D (1), DEF 14A (1), PRE 14A (1), S-1/A (1), S-4 (1), SCHEDULE 13D/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jul 13, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common StockLIMNThe Nasdaq Stock Market LLC
WarrantsLIMNWThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

Legal proceedings

From time to time, we may become involved in actions, claims, litigation, and other legal proceedings occurring in the ordinary course of its business from time to time, including assertions by third parties relating to intellectual property infringement, contract breaches, or employment-related matters. Except as described below, we are not currently a party to any actions, claims, suits, or other legal procedures whose conclusion, if not determined in our favor, would have a major adverse effect on our business, financial condition, or results of operations, either individually or in the aggregate.

On August 4, 2025, Dr. Someit Sidhu (“Dr. Sidhu”) filed a complaint against the Company (collectively, the “Sidhu Matter”) for breach of contract in the New York State Supreme Court, County of New York. Dr. Sidhu alleges the Company breached a certain Letter Agreement for Consulting Services, dated December 8, 2022 (the “Consulting Agreement”) entered into by Dr. Sidhu and Iris prior to the Business Combination by failing to pay Dr. Sidhu an advisory fee of $25,000 (“Advisory Fee”) upon the execution of the Business Combination Agreement, and a $1,400,000 despac success fee (“Despac Fee” together with the Advisory Fee, the “Fees”) upon consummation of the Business Combination. Dr. Sidhu also alleges claims of unjust enrichment and quantum meruit, which likewise arise out of the Company’s alleged failure to pay Dr. Sidhu the Fees. On December 10, 2025, the Company filed a motion to dismiss Dr. Sidhu’s complaint with prejudice, which motion remains pending.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
    SEC EDGAROther events
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37